文献速递认知障碍与痴呆

仑卡奈单抗与唐氏综合征患者脑内血管淀粉样蛋白沉积的结合

Lecanemab and Vascular-Amyloid Deposition in Brains of People With Down Syndrome.
PubMed 文献 · JAMA Neurol · 2024-01-01

该研究分析15例43至68岁唐氏综合征患者尸检脑组织,观察到仑卡奈单抗标记的淀粉样斑块出现在全部15例中,提示潜在靶点结合;但仑卡奈单抗在脑内血管的广泛结合引发安全性担忧,作者认为需在唐氏综合征人群中严格开展临床试验评估安全性和疗效。

要点

  • 仑卡奈单抗标记的淀粉样斑块出现在全部15例唐氏综合征病例中,提示潜在靶点结合。
  • 观察到仑卡奈单抗在唐氏综合征脑内血管的广泛结合,引发显著安全性担忧。
  • 作者认为需在唐氏综合征人群中严格开展临床试验,尤其关注43岁以上者。

核心结论

  • 这些发现提示仑卡奈单抗在唐氏综合征中与脑淀粉样血管病有显著结合。
  • 作者认为应在唐氏综合征人群中严格开展仑卡奈单抗治疗阿尔茨海默病的临床试验,以确定其安全性和疗效,尤其是43岁以上者。

研究设计与样本

  • 研究纳入15例唐氏综合征患者尸检脑组织,年龄43至68岁,来自加州大学欧文分校和肯塔基大学阿尔茨海默病研究中心,获取时间为2008年至2021年。
  • 数据分析时间为2023年8月至2024年5月。
  • 暴露为在脑组织中评估仑卡奈单抗的结合特性。
  • 主要结局为仑卡奈单抗与淀粉样斑块和脑内血管结合的程度。

主要发现

  • 15例唐氏综合征患者中8例为女性(53%),年龄范围43至68岁(均值56.6岁)。
  • 仑卡奈单抗标记的淀粉样斑块出现在全部15例唐氏综合征病例中,提示潜在靶点结合。
  • 观察到仑卡奈单抗在唐氏综合征脑内血管的广泛结合,引发显著安全性担忧。

临床怎么用

  • 作者认为需在唐氏综合征人群中严格开展仑卡奈单抗治疗阿尔茨海默病的临床试验,以确定其安全性和疗效,尤其是43岁以上者。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Anti-β-amyloid immunotherapy using lecanemab is becoming increasingly available to patients with Alzheimer disease (AD). Individuals with Down syndrome (DS) develop AD neuropathology by age 40 years, representing a significant cohort of genetically determined AD. OBJECTIVE: To investigate the binding properties of lecanemab in the brains of people with DS, in anticipation of their inclusion in clinical trials or access to antiamyloid immunotherapies. DESIGN, SETTING, PARTICIPANTS: The study included cases of postmortem brain tissue analysis from 15 individuals with DS aged 43 to 68 years that were acquired from Alzheimer Disease research centers at the University of California, Irvine and the University of Kentucky from 2008 to 2021. Data were analyzed from August 2023 through May 2024. EXPOSURE: The binding properties of lecanemab were assessed in brain tissue. MAIN OUTCOME: The primary outcome was the extent of lecanemab binding to amyloid plaques and brain blood vessels. RESULTS: Tissue from 15 people (8 were female [53%]) with DS ranging in age from 43 to 68 (mean, 56.6) years were included in the study. Lecanemab-labeled amyloid plaques appeared in all 15 DS cases studied, indicating potential target engagement. However, extensive binding of lecanemab to brain blood vessels in DS was observed, raising significant safety concerns. These findings underscore the necessity for clinical trials of lecanemab in people with DS to evaluate both safety and efficacy, particularly in individuals older than 43 years. CONCLUSIONS AND RELEVANCE: These findings suggest significant binding of lecanemab to cerebral amyloid angiopathy in DS. Lecanemab should be rigorously tested in clinical trials for AD in the DS population to determine its safety and efficacy, especially in those older than 43 years.

来源:JAMA Neurol,查看原文。版权归原作者所有。

引用

  1. Liu L, Saba A, Pascual JR, et al. Lecanemab and Vascular-Amyloid Deposition in Brains of People With Down Syndrome. JAMA Neurol. 2024. PMID: 39158850. doi:10.1001/jamaneurol.2024.2579

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。